MOB2 and ovarian cancer: In addition, examination of the publicly available CellMiner database found that ovarian cancer lines with lower MOB2 mRNA levels seem to be more sensitive to olaparib or cisplatin treatments when compared to cells expressing higher MOB2 mRNA levels (Fig. 5E).